Folly, the first biotech-powered hair supplement, has announced its global launch, bringing a clinically potent hair gummy to market and addressing a longstanding issue in the supplement industry: underdosing and inconsistent delivery.
The launch coincides with a follow-on investment led by Khosla Ventures, which will support the global commercialisation of Folly’s microsphere encapsulation platform and expansion into new wellness categories.
Despite the popularity of hair supplements, many products fail to deliver meaningful results. Common issues include:
As a result, patients frequently cycle through products that look promising but fail to deliver clinically relevant results or are too cumbersome to stay on long enough to see benefits.
Folly’s breakthrough comes from applying drug-delivery science to hair supplements. Using Folly Microspheres™, a proprietary microencapsulation system, the supplement:
This approach ensures that nutrients reach the hair follicles effectively, rather than being degraded in the stomach.
Luna Yu, Co-Founder and CEO, explains:
“Folly was built to solve the supplement industry's delivery crisis: ensuring that clinically studied nutrients actually reach your follicles, not your stomach lining. I spent years working in pharmaceutical delivery science before realizing the supplement industry had never fully applied these principles. The same approaches that protect active ingredients in drug delivery can protect nutrients in a gummy. That is what Folly Microspheres do”.
In a 300-person consumer perception study, women using Folly daily for at least 30 days reported:
This demonstrates the potential for a highly effective, user-friendly hair supplement that delivers meaningful outcomes in just 30 days.
Folly will be available in April 2026 in the U.S. and U.K., with expansion planned across Europe and Asia later in the year.
For more information, visit: www.follynutrition.com or follow @FollyNutrition.